Page 1

AIM ImmunoTech Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM Immuno Tech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial , Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Toward Planned Phase 3 Development While Seeking Select Government- Funded Infectious Disease Initiatives in Ebola OCALA , Fla . , August 10 , 2026 / AIM ImmunoTech Inc. ( NYSE American : AIM ) ( " AIM " or the " Company " ) today reported financial results for the second quarter ended June 30 , 2026 , and provided a business update highlighting continued operational execution across its lead pancreatic cancer program . " AIM continues to execute a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer , " said AIM Chief Executive Officer Thomas K. Equels . " Over the past year , we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as we move toward an anticipated Phase 3 study in metastatic pancreatic cancer . We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology - in Q3 2027. AIM expects that this data will amplify median Overall Survival findings from Ampligen's Dutch- government approved Named Patient Program in late - stage pancreatic cancer , where Ampligen achieved a median Overall Survival of 34.8 months compared to 12.5 months for historical controls with favorable safety profile and high quality of life in a large , easily identifiable and key patient immune biomarker subset . This median improvement of 22.3 months will be a critical component of the foundation for our pivotal Phase 3 clinical trial design in metastatic pancreatic cancer . " Second Quarter and Recent Operational Highlights - • Completed patient enrollment and Ampligen dosing in the ongoing Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca's anti - PD - L1 immune checkpoint inhibitor Imfinzi® ( durvalumab ) in metastatic pancreatic cancer . • Engaged Thermo Fisher Scientific's PPD clinical research business to support study design of a planned pivotal Phase 3 clinical trial in metastatic pancreatic cancer . • Maintained encouraging observations from Erasmus MC Cancer Institute , including favorable safety findings , progression - free and overall survival trends , and consistently reported high quality of life among treated patients . 1